SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. B.1.427/B.1.429 S pseudotyped virus neutralization by vaccine-elicited and COVID-19 convalescent plasma. (A, B, E, and F) Neutralizing Ab titers [mean inhibition dilution (ID50)] shown as pairwise connected [(A) and (E)] or GMT [(B) and (F)] against MLV [(A) and (B)] or VSV [(E) and (F)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Moderna mRNA-1273 vaccine (blue). (C, D, G, and H) Neutralizing Ab titers (ID50) shown as pairwise connected [(C) and (G)] or GMT [(D) and (H)] against MLV [(C) and (D)] or VSV [(G) and (H)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine (red). (I and J) Neutralizing Ab ID50 (I) and GMT (J) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from naïve (blue) and previously infected (red) individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine. “Naïve” indicates vaccinated individuals who had not been previously infected with SARS-CoV-2; “immune” refers to vaccinated individuals who had been previously infected with SARS-CoV-2. (K and L) Neutralizing Ab ID50 (K) and GMT (L) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from convalescent individuals who were infected with WT SARS-CoV-2. Neutralization data shown in (A) to (H) and (I) to (L) were performed using 293T-ACE2 and VeroE6-TMPRSS2, respectively. Data are average of n = 2 replicates.](https://figures.cochat.ai/paper-figures/e2b6f8f874fc4753bb3a1e70b39ac8ee/sars-cov-2-immune-evasion-by-the-b-1-427-b-1-429-variant-of-concern-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This signal peptide modification resulted in a total loss of neutralization by ten NTD-specific antibodies [40].”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant 99,104,221 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [221]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A novel mechanism of immune evasion was studied in the Epsilon variant, where the other two mutations remodeled NTD by shifting the signal peptide cleavage site in the NTD antigenic supersite and forming a new disulfide bond.”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citationLiebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621
Cited by
Items 301–400 of 426
Osorio, M. I., Yáñez, O., Gallardo, M. O., Zúñiga-Bustos, M., Mulia-Rodríguez, J., López-Rendón, R., García‐Beltrán, O., González-Nilo, F. D., & Perez-Donoso, J. M. (2022) · Pharmaceuticals · doi:10.3390/ph15080986 · Cited by 7
“This variant presents mutations that decrease the effectiveness of the antibodies, whether they are monoclonal, generated by a previous SARS-CoV-2 infection or those obtained by the vaccine against the virus [4,5].”
BackgroundCombination of Recombinant Proteins S1/N and RBD/N as Potential Vaccine Candidates
Mendoza‐Ramírez, N. J., García‐Cordero, J., Martínez-Frías, S. P., Roa-Velázquez, D., Luría-Pérez, R., Bustos‐Arriaga, J., Hernández, J., Cabello-Gutiérrez, C., Zúñiga, J., Morales‐Ríos, E., et al. (2023) · Vaccines · doi:10.3390/vaccines11040864 · Cited by 8
Complex vaccination strategies prevent the emergence of vaccine resistance
Rella, S. A., Kulikova, Y. A., Minnegalieva, A. R., & Kondrashov, F. A. (2024) · Evolution · doi:10.1093/evolut/qpae106 · Cited by 6
“SARS-CoV-2 rapidly evolved variants with a much higher infectivity (Soh et al. 2021) and showed a tendency to avoid vaccines (Planas et al. 2022; McCallum et al. 2021), both of these factors may have been driven by evolution of SARS-CoV-2 in immunocompromised patients (Sonnleitner et al. 2022).”
BackgroundHognon, C., Bignon, E., Monari, A., Marazzi, M., & García‐Iriepa, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032517 · Cited by 6
“Indeed, the L452R mutation of the Delta variant is associated with immune system escape, resulting in a transmissibility improvement [35,39,40].”
BackgroundHow Is Mass Spectrometry Tackling the COVID-19 Pandemic?
Ibáñez, A. J. (2022) · Frontiers in Analytical Science · doi:10.3389/frans.2022.846102 · Cited by 5
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031646 · Cited by 6
“429 (epsilon) variants in the SARS-CoV-2 S protein affect 115 conformational landscapes of the S protein and the ability to evade host immunity and incur 116 resistance to antibodies [59-69].”
BackgroundPetersen, J. D., Lu, J., Fitzgerald, W., Zhou, F., Blank, P. S., Matthies, D., & Zimmerberg, J. J. (2022) · Viruses · doi:10.3390/v14051024 · Cited by 7
Relative Infectivity of the SARS-CoV-2 Omicron Variant in Human Alveolar Cells
Kim, T., Min, K. I., Yang, J., Kim, J. W., Cho, J., Kim, Y. H., Lee, J. S., Kim, Y. T., Kim, K.-C., Kim, J. Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105571 · Cited by 5
Vaccination against SARS-CoV-2 should be included in childhood vaccination programs
Petersen, E., & Buchy, P. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.082 · Cited by 6
Tuccori, M., Convertino, I., Ferraro, S., Cappello, E., Valdiserra, G., Luca, G. D., Franchini, M., & Focosi, D. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2058486 · Cited by 4
“20C/L452R West Coast variant =([56]) =([56])”
Tang, H., Ke, Y., Wang, L., Wu, M., Sun, T., & Zhu, J. (2022) · Pharmaceuticals · doi:10.3390/ph15081002 · Cited by 4
Different Variants of SARS-CoV-2: A Comprehensive Review on Mutation Patterns and Pathogenicity
Rizvi, F., Khan, M. A., Ansari, W. A., Ali, K., Khan, M. A., & Khan, M. A. (2023) · Coronaviruses · doi:10.2174/2666796704666230328171636 · Cited by 5
Dor, G., Kekana, D., Hisner, R., Martin, D. P., Korber, B., Ernst, T., Levy, A., Speers, D. J., Turville, S. G., Sintchenko, V., et al. (2025) · medRxiv · doi:10.64898/2025.12.19.25342658 · Cited by 5
Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections
Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Lau, B., Liang, C.-Y., Burgess, J. L., Ellingson, K., Beitel, S. C., Romine, J. K., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02162-2 · Cited by 6
Felbinger, N. R., Trudil, D., Loomis, L. D., Ascione, R., Siragusa, G. R., Haba, S., Rastogi, S., Mucci, A., Claycomb, M., Snowberger, S., et al. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.988109 · Cited by 5
Severe COVID-19: Drugs and Clinical Trials
Ceja-Gálvez, H. R., Renteria-Flores, F. I., Nicoletti, F., Hernández‐Bello, J., Ojeda, G. M., & Muñóz-Valle, J. F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082893 · Cited by 5
Evaluation of Potential Peptide‐Based Inhibitors against SARS‐CoV‐2 and Variants of Concern
Boshah, H., Samkari, F., Valle-Pérez, A. U., Alsawaf, S. M., Aldoukhi, A. H., Bilalis, P., Alshehri, S., Susapto, H. H., & Hauser, C. A. E. (2023) · BioMed Research International · doi:10.1155/2023/3892370 · Cited by 4
Kharchenko, E. P. (2021) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2021-20-4-4-18 · Cited by 4
Murugadoss, K., Niesen, M. J. M., Raghunathan, B., Lenehan, P. J., Ghosh, P., Feener, T., Anand, P., Simsek, S., Suratekar, R., Hughes, T. K., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac018 · Cited by 4
Wang, Q., Lü, P., Nie, Y., Shu, Y., Zhang, H., Song, Z., Li, Y., Hu, H., Li, L., Wang, X., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.12.007 · Cited by 4
SARSMutOnto: An Ontology for SARS-CoV-2 Lineages and Mutations
Bakkas, J., Hanine, M., Abderrahman, C., Gounane, S., Díez, I. D. L. T., Lipari, V., López, N. M. M., & Ashraf, I. (2023) · Viruses · doi:10.3390/v15020505 · Cited by 4
“Examples of these lineages include B.1.427/B. 1.429 [35] assigned by the WHO with the Greek letter Epsilon.”
BackgroundInfluentialYeh, Y., Chao, T., Chang, Y.-J., Chang, S., Lu, C., Chao, C., Su, W., Tseng, C., Lai, M. M. C., & Cheng, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317040 · Cited by 4
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac125.68956914 · Cited by 8
“Moreover, this variant exhibits a new deletion and multiple non-synonymous mutations in the spike genes, including Δ246-252, G75V, T76I, L452Q, F490S, D614G, and T859N) [3- 5].”
BackgroundMethodInfluentialPlummer, J., Contreras, D. A., Zhang, W., Binek, A., Zhang, R., Dezem, F. S., Chen, S. S., Davis, B. D., Martínez, J., Stotland, A. B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac295 · Cited by 5
“To address this, nonvariant and epsilon variant serum were used to test whether this variant is as sensitive to NAbs [12].”
InfluentialThe in vitro and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2Preprint
Ryu, D.-K., Woo, H., Kang, B., Noh, H., Kim, J., Seo, J.-M., Kim, C.-M., Kim, M., Kim, J., Kim, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.23.453472 · Cited by 8
Cao, L., Li, Y., Yang, S., Li, G., Zhou, Q., Sun, J., Xu, T., Yang, Y., Zhu, T., Huang, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.13.463130 · Cited by 4
“…vaccine-induced or naturally acquired protective herd immunity to interruption of transmission chains had been hampered by the rapid evolution and recurrent emergence of SARS-CoV-2 variants, such as Delta variant, one of the major variants of concern (VOC) (Liu et al. 2021; McCallum et al. 2021).”
BackgroundConformational dynamics and allosteric modulation of the SARS-CoV-2 spikePreprint
Díaz-Salinas, M. A., Li, Q., Ejemel, M., Yurkovetskiy, L., Luban, J., Shen, K., Wang, Y., & Munro, J. B. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.29.466470 · Cited by 4
Addetia, A., Schäfer, A., Sprouse, K. R., Valdez, A., Taylor, A., Navarro, M.-J., Brown, J. T., Leaf, E. M., Miranda, M. C., Walls, A. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.11.652904 · Cited by 4
Self-citationSantos, T. M., Lisboa, A. B. P., Rodrigues, W. F. C., Gomes, H., Abrahão, J. S., & Del‐Bem, L. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2042387 · Cited by 3
“It is known that SARS-CoV-2 genetic variation is an important factor when considering transmissibility, disease outcome and antibody escape (Davies et al., 2021; McCallum et al., 2021; Wang et al., 2021).”
BackgroundA Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions
Springstein, B. L., Deighan, P., Grabe, G. J., & Hochschild, A. (2021) · mBio · doi:10.1128/mbio.02936-21 · Cited by 4
Estimated change of COVID-19 vaccine efficacy due to omicron variant SARS CoV2.
Mungmunpuntipantip, R., & Wiwanitkit, V. (2022) · PubMed Central · Cited by 3
Lao, T., Avalos, I., Rodríguez, E. R., Zamora, Y., Rodríguez, A., Ramòn, A. C., Alvarez, Y., Cabrales, A., Andújar, I., González, L. J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288006 · Cited by 4
Variant-specific RT-qPCR for rapid screening of B.1.617 mutations in SARS-CoV-2
Jallul, M., Ibrahim, K., Zaghdani, A. A., Abdusalam, M. M., Dwigen, S. M. A., Atwair, W. S., Elbasir, M., Alhudiri, I. M., Meshri, S. E. E., & Elzagheid, A. I. (2022) · Libyan Journal of Medicine · doi:10.1080/19932820.2022.2121252 · Cited by 3
Natural heteroclitic-like peptides are generated by SARS-CoV-2 mutations
Tiezzi, C., Vecchi, A. L., Rossi, M., Cavazzini, D., Bolchi, A., Laccabue, D., Doselli, S., Penna, A., Sacchelli, L., Brillo, F., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106940 · Cited by 3
Self-citationMoisan, A., Soares, A., Oliveira, F. D., Alessandri-Gradt, É., Lecoquierre, F., Fourneaux, S., Plantier, J., & Gueudin, M. (2023) · Viruses · doi:10.3390/v15051115 · Cited by 4
Comparative Analysis and Classification of SARS-CoV-2 Spike Protein Structures in PDB
Aslam, M., Nawaz, M. S., Fournier‐Viger, P., & Li, W. (2023) · COVID · doi:10.3390/covid3040034 · Cited by 3
“[46] discussed the properties of the S protein of the Epsilon variant.”
BackgroundStructural Ramifications of Spike Protein D614G Mutation in SARS-CoV-2Preprint
Dokainish, H. M., & Sugita, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.24.477651 · Cited by 3
A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccinesPreprint
Lee, J., Stewart, C., Schaefer, A., Leaf, E. M., Park, Y., Asarnow, D. E., Powers, J. M., Treichel, C., Corti, D., Baric, R. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.12.571160 · Cited by 3
Self-citationSARS-CoV-2 and chronic kidney disease: challenges and future directions
Olivier, G., & Elzi, L. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102642 · Cited by 2
Apps, R., Polanco, J. J., Lowman, K. E., Wang, L., Cheung, F., Kotekar, A., Koroleva, G., Mukherjee, A., Ylade, M. C., Crisostomo, M. V., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf301 · Cited by 2
SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_7 · Cited by 4
The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution
Wu, C., Yang, Y., Lin, Y., Shu, L., Cheng, Y., Liu, H.-T., Lin, Y.-Y., Lee, I., Shih, W., Yang, P., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17701 · Cited by 2
Maxwell, J. W. C., Stockdale, S., Stewart, E. L., Ashley, C. L., Smith, L. J., Steain, M. C., Triccas, J. A., Byrne, S. N., Britton, W. J., Ashhurst, A. S., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00544 · Cited by 2
Structure and function of an unusual R452-dependent monoclonal antibody against SARS-CoV-2
Zhou, B. N., Gui, Q., Liu, C., Guo, H., Wang, H., Cheng, L., Fan, Q., Ge, X., Zhang, Z., & Ju, B. (2025) · Journal of Virology · doi:10.1128/jvi.01844-24 · Cited by 2
“The L452R mutation on the RBD of the spike protein of SARS-CoV-2 is a critical determinant for antibody escape (30, 31), having a significant influence on the interaction between the virus and nAbs.”
Kekana, D., Ntozini, B., Hisner, R., Yousif, M., Ntuli, P., Ndlovu, N., McCarthy, K., Mnguni, A., Mahlangu, B., Nzimande, A., et al. (2025) · Virus Evolution · doi:10.1093/ve/veaf083 · Cited by 1
“Several mutations at the N-terminal end of Spike, including P9L,S12P,and S13I,have been shown to alter the location of signal peptide cleavage, resulting in the loss of S:C15 (McCallum et al. 2021a; Yu et al. 2023).”
InfluentialNovel Coronavirus National Science and Technology Resource Service System
Ma, J., Wu, L., & Zhang, J. (2024) · Springer eBooks · doi:10.1007/978-981-99-8270-7_19 · Cited by 2
Perbolianachis, P., Ferla, D., Arce, R., Ferreiro, I., Costábile, A., Paz, M., Simón, D., Moreno, P., & Cristina, J. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198688 · Cited by 2
Rahman, S. M. A., Shishir, M. A., Hosen, M. I., Khan, M. J., Arefin, A., & Khandaker, A. M. (2022) · Gene Reports · doi:10.1016/j.genrep.2022.101608 · Cited by 5
“…UK, September 2020), B.1.351 (South Africa, December 2020), P.1 (Detected in Japan from Brazilian travelers, January 2021), B.1.427/B.1.429 (USA, February 2021) and B.1.617.2 (India, 2021) variants (Davies and Jarvis, 2021; Zhou et al., 2021; Sabino et al., 2021; McCallum et al., 2021; Adam, 2021).”
InfluentialYoon, S., Anaya, E., Sachithanandham, J., Pinsky, B. A., Sullivan, D. J., Mostafa, H. H., & Pekosz, A. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.03.531067 · Cited by 2
“88 The D614G substitution is found in all variants of concern (VOCs), while L452R, demonstrated to 89 improve viral infectivity, fusogenicity and evasion of cellular and humoral immunity [21-23], is found in 90 both Delta (B.”
BackgroundSialylated porphyrins optimized as anti-infective agents against SARS-CoV-2 variants
Lioret, V., Gillot, C., Hologne, M., Ha, J., Strilets, D., Scampamorte, L. L. D., Gillet, L., Douxfils, J., & Vincent, S. P. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109519 · Cited by 1
RECUR: identifying recurrent amino acid substitutions from multiple sequence alignments
Robbins, E. H. J., Liu, Y., & Kelly, S. L. (2026) · Molecular Biology and Evolution · doi:10.1093/molbev/msag036 · Cited by 3
NTD Remodeling in the SARS-CoV-2 BA.3.2 Variant May Influence Spike Stability and Immune Escape
Quaranta, M., Ciccozzi, A., Branda, F., Sernicola, L., Ciccozzi, M., Pascarella, S., Borsetti, A., & Scarpa, F. (2026) · Pathogens · doi:10.3390/pathogens15070760 · Cited by 1
Ferreira, C., Doursout, M.-F. J., & Balingit, J. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-10035-2_7 · Cited by 1
S, B. G. A., & Gracia, J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2263798 · Cited by 1
“…Enzyme (hACE2) through which cell entry for SARS-CoV-2 is mediated and Immune evasion mediated by decreased affinity for neutralizing antibody binding (Beyer & Forero, 2022; Cai et al., 2021; Chen et al., 2022; Lazarevic et al., 2021; McCallum, Bassi et al., 2021; McCallum, Walls, et al., 2021).”
Visualizing of engineered five-helix bundle protein for blocking SARS-CoV-2 variants in live animals
Xian, J., Li, Z., Huang, H., Bi, L., Guan, Z., Huang, G., Yang, M., Gao, Z., Yao, J., Su, Z., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155827 · Cited by 1
Okamasa, A., Okour, M., Austin, D. J., Shida, Y., Sager, J. E., Alexander, E. L., Brintziki, D., Haggag, A. Z., HARRISON, S. A., HATTORI, T., et al. (2022) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.96.39 · Cited by 1
Can we Succeed in the Fight Against SARS-CoV-2 with its Emerging New Variants?
Tavakol, S., Tavakol, H., Alavijeh, M. S., & Seifalian, A. M. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220506142117 · Cited by 2
Will New Variants Emerge after Delta and Omicron?
Yang, Z. L., Zhang, S., Tang, Y., Yue, S., Xu, D.-Q., Fu, R., Zhang, S., & Liu, Q. (2022) · Aging and Disease · doi:10.14336/ad.2022.0307 · Cited by 2
“In addition, it was related with increased ACE2 binding, expanded infectivity, and a 3-6-fold decrease in neutralization susceptibility to vaccine-initiated serum in pseudotyped virus (PV) particle experiments [11, 12].”
BackgroundDevelopment and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 InfectionPreprint
Ismail Yilmaz, C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Aydin, Y., Guvencli, N., Gungor, B., et al. (2021) · Authorea · doi:10.22541/au.162615692.26217047/v2 · Cited by 1
RBD-IgG levels correlate with protection in Residents Facing SARS-CoV-2 B.1.1.7 OutbreaksPreprint
Blain, H., Tuaillon, É., Gamon, L., Pisoni, A., Miot, S., Delpui, V., Si-Mohamed, N., Niel, C., Rolland, Y., Montès, B., et al. (2021) · doi:10.22541/au.163254719.96929295/v1 · Cited by 1
Tang, H., Ke, Y., Ma, H., Han, L., Wang, L., Zong, H., Yuan, Y., Wang, Z., He, Y., Chang, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.17.475291 · Cited by 2
“Escape information refers to COG-UK-ME and literatures of corresponding antibodies: Etesevimab [18], Casirivimab [17-20], Tixagevimab [25], ABBV-2B04 [26], Regdanvimab [12], Bamlanivimab [17], Cilgavimab [25], Imdevimab [18,19], ADG20 [17].”
BackgroundBroad neutralization of SARS-CoV-2 variants by circular mRNA producing VFLIP-X spike in micePreprint
Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.17.484759 · Cited by 1
Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 InfectionPreprint
Ismail Yilmaz, C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Aydin, Y., Guvencli, N., Gungor, B., et al. (2021) · Authorea · doi:10.22541/au.162615692.26217047/v1 · Cited by 1
The DARPin Encyclopedia: from Basic Research towards TherapeuticsPreprint
Wild, P. S., Eapen, R., Forrer, P., & Jost, C. (2022) · Preprints.org · doi:10.20944/preprints202206.0147.v3 · Cited by 2
Schmidt, J., Blessing, F., & Gürtler, L. G. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1550-0001
“1429) scheint schwerer neutralisierbar zu sein [31].”
BackgroundNetwork analysis outlines strengths and weaknesses of emerging SARS-CoV-2 Spike variantsPreprint
Manrique, P. D., Chakraborty, S., Nguyen, K., Mansbach, R. A., Korber, B., & Gnanakaran, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.03.458946
A bacteria-based assay to study SARS-CoV-2 protein-protein interactionsPreprint
Springstein, B. L., Deighan, P., Grabe, G., & Hochschild, A. (2021) · bioRxiv · doi:10.1101/2021.10.07.463611
BARREIRA HEMATOENCEFÁLICA, EIXO GASTROINTESTINAL-SNC E INFECÇÃO PELO SARS-COV2
Arnholdt, A. C. V. (2021) · doi:10.22533/at.ed.30721041111
A PESSOA COM DEFICIÊNCIA VISUAL NO CONTEXTO DA PANDEMIA DO COVID-19
Figueiredo, E. L. A., Brandolin, F., Oliveira, I. J. D. A. S., Figueiredo, J. R. M., de Oliveira, J. T. M., & Abade, M. L. (2021) · doi:10.22533/at.ed.30721041115
PRÁXIS DA FISIOTERAPIA NA SINDEMIA POR COVID-19: CONTEXTUALIZAÇÃO E PROGNOSE
Pereira, C. M. D. S., Oliveira, I. J. D. A. S., de Oliveira, J. T. M., Fraga, M. C., de Lima, R. P., Ribeiro, S. D. S., & de Souza, M. F. (2021) · doi:10.22533/at.ed.30721041114
FATORES GENÉTICOS E EPIGENÉTICOS RELACIONADOS À COVID-19
Colete, C. C. F. A., Martins, L. M., & Mangiavacchi, P. M. (2021) · doi:10.22533/at.ed.3072104112
Curcio, F. S., da Costa, H. M. V., Rangel, T. L. V., Mangiavacchi, B. M., & Dellatorre, R. D. S. Z. (2021) · doi:10.22533/at.ed.3072104119
Nunes, C. D. R., Curcio, F. S., & Borges, T. R. B. (2021) · doi:10.22533/at.ed.3072104115
Rangel, T. L. V., Curcio, F. S., & da Costa, H. M. V. (2021) · doi:10.22533/at.ed.3072104114
Some Bioinformatics Studies on SARS-CoV-2
Mitra, S. (2021) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-m4k7-3914
Martini, L., & Brzeziński, P. (2021) · Our Dermatology Online · doi:10.7241/ourd.2021e.93
“And therefore the AA decided to analyze first the epsilon variant [2].”
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.09.471953
Jayatilaka, G., Hassan, J., Sritharan, S., Senanayaka, J. B., Weligampola, H., Godaliyadda, R. I., Ekanayake, P., Herath, V. R., Ekanayake, J. B., & Dharmaratne, S. D. (2022) · Applied Sciences · doi:10.3390/app12178428 · Cited by 2
Lee, D. B., Kim, H., Jeong, J. H., Jang, U. S., Chang, Y. Y., Roh, S., Jeon, H., Kim, E. J., Han, S. Y., Maeng, J. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.18.480994
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.11.487920
Felbinger, N. R., Trudil, D., Loomis, L. D., Ascione, R., Siragusa, G. R., Haba, S., Rastogi, S., Mucci, A., Claycomb, M., Snowberger, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.13.487697
“Although these mutations are not believed to directly affect the ACE2 binding activity of the virus, they are located in a peptide stretch that has been identified as an epitope for neutralizing antibodies and are thought to help inhibit neutralizing activity (28).”
Petersen, J. D., Lu, J., Fitzgerald, W., Zhou, F., Blank, P. S., Matthies, D., & Zimmerberg, J. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.07.487415
“The Delta variant’s spike displayed a different combination of mutations compared to Alpha, that were predicted to reduce sensitivity to neutralizing antibodies [39-41] and increase ACE2 receptor binding, spike stability, viral infectivity, fusogenicity, and pathogenicity [42-44].”
BackgroundSARS-CoV-2: overview of immune response, insights into vaccine platforms and their challenges
Omar, B. J., Singh, A., Singh, V., Kothari, A., & Pai, M. O. (2022) · Exploration of Immunology · doi:10.37349/ei.2022.00049
The DARPin Encyclopedia: from Basic Research Towards TherapeuticsPreprint
Wild, P. S., Eapen, R., Forrer, P., & Jost, C. (2022) · Preprints.org · doi:10.20944/preprints202206.0147.v1 · Cited by 1
The DARPin Encyclopedia: from Basic Research Towards TherapeuticsPreprint
Wild, P. S., Eapen, R., Forrer, P., & Jost, C. (2022) · Preprints.org · doi:10.20944/preprints202206.0147.v2
Murugadoss, K., Neisen, M., Raghunathan, B., Lenehan, P. J., Ghosh, P., Feener, T., Anand, P., Şimşek, Ş., Suratekar, R., Hughes, T., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3993373
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Sisakht, M. M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1826408/v1
Hartley, G. E., Edwards, E. S. J., Varese, N. P., Boo, I., Aui, P. M., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., & van Zelm, M. C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.03.502703
Turabián, J. L. (2022) · Journal of Diseases Disorders & Treatments · doi:10.47363/jddt/2022(2)117
Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against OmicronPreprint
Chi, X., Xia, L., Zhang, G., Chi, X., Huang, B., Zhang, Y., Chen, Z., Han, J., Wu, L., Li, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.25.509344
S, B. G. A. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-88rxb
Siewiński, M., Bażanów, B., Orzechowska, B., Gołąb, K., Gburek, J., Matkowski, A., Rapak, A., Janocha, A., Krata, L., Dobrzyński, M., et al. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110965 · Cited by 2
Immunization of MERS-CoV-2-infected mice with a sublethal dose of MERS-CoV or VRP-MERS-S
Zheng, J. H., Channappanavar, R., & Perlman, S. M. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102171
Abeygoonawardena, H., Jayasinghearachchi, H. S., Senaratne, T., Jayasekera, P. T., Nakkawita, D., Mubarak, N., Kulasekera, U., Kawyangana, P., Govindapala, D., & Silva, A. D. D. (2023) · Sri Lankan Journal of Infectious Diseases · doi:10.4038/sljid.v13i1.8512
Khorattanakulchai, N., & Phoolcharoen, W. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.292
Mohapatra, R. K., Seidel, V., Kandi, V., & Rabaan, A. A. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-3603-2
The Covid-19 and TB Syndemic: Differences and Similarities
Kaufmann, S. H. E., Sher, A., Sigal, A., & Sawitzki, B. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-4116-6
Osorio, M. I., Yáñez, O., Gallardo, M. O., García‐Beltrán, O., González-Nilo, F. D., & Perez-Donoso, J. M. (2022) · Authorea · doi:10.21203/rs.3.rs-1612764/v1
Yang, Y., Lin, Y.-J., You, S., Lu, T., Chen, C., Wang, W.-M., Ling, M., Chen, S., & Liao, C. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s480086
“43,44 Compared to other variants, more mutations on both spike protein and non-spike protein genes provided Omicron variant with additional entry pathways (endocytic and receptor-mediated endocytosis) to increase transmissibility and infectivity, as well as to evade vaccinations and antibodies.”
Background
Metadata
- Authors
- McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Sprouse, K. R., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., Guastalla, S. B., Bona, G., Pellanda, A. F., Garzoni, C., Van Voorhis, W. C., Rosen, L. E., Snell, G., Telenti, A., Virgin, H. W., Piccoli, L., Corti, D., & Veesler, D.
- Affiliations
- University of Washington (US)
- Vir Biotechnology (Switzerland) (CH)
- Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
- VIR Biotechnology (United States) (US)
- Vir Biotechnology, San Francisco, CA 94158, USA.
- Independent physician, 6828 Balerna, Switzerland.
- Clinica Luganese Moncucco (CH)
- Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
- Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
- Corresponding author
- McCallum, Matthew
- Bassi, Jessica
- Chen, Alex
- Walls, Alexandra C.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- ORCID
- McCallum, Matthew
- Bassi, Jessica
- De Marco, Anna
- Chen, Alex
- Walls, Alexandra C.
- Di Iulio, Julia
- Tortorici, M. Alejandra
- Navarro, Mary-Jane
- Saliba, Christian
- Sprouse, Kaitlin R.
- Pinto, Dora
- Culap, Katja
- Bianchi, Siro
- Jaconi, Stefano
- Cameroni, Elisabetta
- Bowen, John E.
- Tilles, Sasha W.
- Pizzuto, Matteo Samuele
- Guastalla, Sonja Bernasconi
- Bona, Giovanni
- Pellanda, Alessandra Franzetti
- Garzoni, Christian
- Van Voorhis, Wesley C.
- Rosen, Laura E.
- Snell, Gyorgy
- Telenti, Amalio
- Virgin, Herbert W.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- Venue
- Science
- Published
- 2021-08-06
- Volume
- 373
- Issue
- 6555
- Pages
- 648-654
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9835956
- OpenAlex
- W3174747632
- Cited by
- 412
- References
- 90
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 25 · 2023: 56 · 2022: 165 · 2021: 141
- FWCI
- 31.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (DP1AI158186, HHSN272201700059C, U01 AI151698-01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, immune evasion, spike protein mutations, L452R, N-terminal domain, receptor binding domain, neutralizing antibodies, monoclonal antibodies, signal peptide cleavage site, disulfide bonds, mRNA vaccines, convalescent plasma, neutralization titers
- MeSH terms
- Protein Domains, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Monoclonal, Antibodies, Viral, Antigens, Viral, Humans, Models, Molecular, Mutation, Neutralization Tests, Protein Conformation, Amino Acid Substitution, Cryoelectron Microscopy, Protein Subunits, Protein Interaction Domains and Motifs, Immune Evasion, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.